Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | ALPL | P05186 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TTK | P33981 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | RARG | P13631 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29733448 | 0.79 | KDM4E (0.52) | KDM4EGAAPDPK1CYP3A4IDO1 | |
| SCHEMBL1290531 | 0.79 | KDM4E (0.52) | KDM4EGAAPDPK1CYP3A4IDO1 | |
| SCHEMBL2851022 | 0.79 | KDM4E (0.52) | KDM4EGAAPDPK1CYP3A4IDO1 | |
| SCHEMBL224732 | 0.79 | KDM4E (0.52) | KDM4EGAAPDPK1CYP3A4IDO1 | |
| SCHEMBL16303429 | 0.76 | KDM4E (0.48) | KDM4EGAAPDPK1CYP3A4IDO1 | |
| SCHEMBL17887974 | 0.76 | KDM4E (0.48) | KDM4EGAAPDPK1CYP3A4IDO1 | |
| SCHEMBL7982776 | 0.75 | KDM4E (0.48) | KDM4EGAAPDPK1CYP3A4IDO1 | |
| SCHEMBL24358756 | 0.73 | PDPK1 (0.58) | PDPK1IDO1CDK2FLT3 | |
| SCHEMBL15312579 | 0.73 | ITK (0.46) | GAAALDH1A1ITKMAP2K4 | |
| SCHEMBL15312372 | 0.73 | MAP2K4 (0.51) | ITKMAP2K4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3538101-B1 | INHIBITORS OF CANCER AND/OR METASTASIS | UNIV VIRGINIA COMMONWEALTH (US) | 2024-06-19 | — | — | EP | disclosed |
| US-11891399-B2 | Inhibitors of cancer invasion, attachment, and/or metastasis | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2024-02-06 | — | — | US | disclosed |
| US-20220127254-A1 | INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2022-04-28 | — | — | US | disclosed |
| EP-3924340-A1 | INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | Merck Patent GmbH (DE) | 2021-12-22 | — | — | EP | disclosed |
| CN-113474334-A | Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer | 默克专利股份公司 | 2021-10-01 | — | — | CN | disclosed |
| US-20210214365-A1 | INHIBITORS OF CANCER INVASION, ATTACHMENT, AND/OR METASTASIS | Sanford Burnham Prebys Medical Discovery Institute | 2021-07-15 | — | — | US | disclosed |
| US-11008325-B2 | Inhibitors of cancer invasion, attachment, and/or metastasis | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2021-05-18 | — | — | US | disclosed |
| WO-2020165062-A1 | INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2020-08-20 | — | — | WO | disclosed |
| EP-3538101-A1 | INHIBITORS OF CANCER INVASION, ATTACHMENT, AND/OR METASTASIS | Virginia Commonwealth University (US) | 2019-09-18 | — | — | EP | disclosed |
| US-20190263824-A1 | INHIBITORS OF CANCER INVASION, ATTACHMENT, AND/OR METASTASIS | VIRGINIA COMMONWEALTH UNIVERSITY | 2019-08-29 | — | — | US | disclosed |
| US-9073892-B2 | Indazolyl triazol derivatives | MERCK SERONO S.A. (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9073892-B2 | Indazolyl triazol derivatives | MERCK SERONO S.A. (CH) | 2015-07-07 | — | — | US | disclosed |
| CN-103429585-A | Indazolyl triazole derivatives as interleukin-1 receptor associated kinase inhibitors | MERCK SERONO SA | 2013-12-04 | — | — | CN | disclosed |
| EP-2655357-A1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | Merck Serono S.A. (CH) | 2013-10-30 | — | — | EP | disclosed |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) | 2013-10-17 | — | — | US | disclosed |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) | 2013-10-17 | — | — | US | disclosed |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) | 2013-10-17 | — | — | US | disclosed |
| WO-2012111017-A1 | 3-ARYLETHYNYL SUBSTITUTED QUINAZOLINONE COMPOUNDS | CONCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-08-23 | — | — | WO | disclosed |
| WO-2012084704-A1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | MERCK SERONO S.A. (CH) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012084704-A1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | MERCK SERONO S.A. (CH) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891399-B2 | Inhibitors of cancer invasion, attachment, and/or metastasis | SDCBP, SDC1, SDAD1 | KDM4E 3578/4885GAA 4453/4885PDPK1 1074/4885 |
| US-20210214365-A1 | INHIBITORS OF CANCER INVASION, ATTACHMENT, AND/OR METASTASIS | SDCBP, SDC1, SDAD1 | KDM4E 3578/4885GAA 4453/4885PDPK1 1074/4885 |
| US-20190263824-A1 | INHIBITORS OF CANCER INVASION, ATTACHMENT, AND/OR METASTASIS | SDCBP, SDC1, SDAD1 | KDM4E 3578/4885GAA 4453/4885PDPK1 1074/4885 |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | NFATC1, IL5, CD4 | KDM4E 3415/4885GAA 3322/4885PDPK1 948/4885 |
| US-20220127254-A1 | INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | KIT, TNNI3K, CILK1 | KDM4E 838/4885GAA 988/4885PDPK1 128/4885 |
| US-11008325-B2 | Inhibitors of cancer invasion, attachment, and/or metastasis | SDCBP, SDC1, SDAD1 | KDM4E 3578/4885GAA 4453/4885PDPK1 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.